Cardiac Troponin I Concentration May Predict Mortality

In HealthDay News
by Healthday

Independent association seen in unselected cohort in whom cTnI was measured, regardless of clinical indication for testing

By Elana Gotkine HealthDay Reporter

THURSDAY, Aug. 10, 2023 (HealthDay News) — Cardiac troponin I (cTnI) concentration is associated with medium-term mortality in an unselected hospital population, according to a study published online Aug. 7 in Heart.

Jonathan Hinton, from the University of Southampton in the United Kingdom, and colleagues conducted a prospective observational study including 20,000 consecutive in-hospital and outpatient patients who had a blood test for any reason at a large teaching hospital and in whom a high-sensitivity cTnI assay was measured.

Overall, 91.4 percent of the patients did not have a clinical indication for cTnI testing. The researchers found that 14.1 percent of patients died at a median of 809 days. If the cTnI concentration was above the upper limit of normal, mortality was significantly higher (45.3 versus 12.3 percent). In a multivariable analysis, log10 cTnI concentration was independently associated with mortality (hazard ratio, 1.76). The relationship persisted in a landmark analysis, excluding deaths within 30 days.

“These findings suggest that a snapshot cTn in a hospital population may represent a biomarker of overall medium-term mortality,” the authors write.

One author disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Copyright © 2023 HealthDay. All rights reserved.